Last year, the Food and Drug Administration (FDA) granted approval for CRISPR's gene therapy for sickle cell disease for ...

July 30, 2024 — A research group has developed a new method that further improves the existing CRISPR/Cas technologies: it allows a more precise and seamless introduction of tags into proteins ...

View full profile. Learn about our editorial policies. Like the human immune system, bacteria learn from past infections. CRISPR sequences—short snippets of DNA from previous viruses—guide destructive ...

CRISPR is a technology that can be used to edit genes and, as such, will likely change the world. The essence of CRISPR is simple: it’s a way of finding a specific bit of DNA inside a cell.

Consider looking at millions upon millions of genetic mutations. With CRISPR gene-editing technology a select few of these mutations might have therapeutic potential, but discovering and then ...

As campaigns increasingly communicate via meme, cat videos are outranking reality. By Charles Homans Follow along with live updates on the Trump and Harris campaigns. By the time the Arizona ...

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform.

CRISPR-Cas9 genome editing exploits the CRISPR-Cas system to modify a genome in a targeted manner. Guided by RNA, the Cas9 endonuclease breaks DNA at a target sequence. Imprecise repair of the ...

CREME is a virtual laboratory that allows scientists to simulate specific decreases in gene activity. It offers a powerful new tool for identifying and understanding important parts of the genome.

Casgevy is now active across 35 Advanced Treatment Centres. Crispr Therapeutics 40% share in Casgevy could result in revenue annual between $1.2 billion and $2.8 billion towards the end of the decade.

More information: Marvin Collins et al, A frugal CRISPR kit for equitable and accessible education in gene editing and synthetic biology, Nature Communications (2024). DOI: 10.1038/s41467-024 ...

In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $45.71, indicating a +0.29% shift from the previous trading day. We’re only a few months a way from the end of the ...